Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation - PubMed (original) (raw)
Clinical Trial
. 1988 Jan-Mar;6(1):7-12.
doi: 10.1002/hon.2900060103.
Affiliations
- PMID: 3277904
- DOI: 10.1002/hon.2900060103
Clinical Trial
Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation
C Shustik et al. Hematol Oncol. 1988 Jan-Mar.
Abstract
The effect of early therapy on the course of chronic lymphocytic leukemia (CLL) has not been established. Fifty-nine patients with indolent Rai stage I and II CLL were randomized to receive intermittent chlorambucil once a month or to receive no treatment. The two groups were comparable in entry characteristics. At 5 years from randomization there was no significant difference in survival between the two groups although the proportion of patients exhibiting active disease 5 years after randomization is 70 per cent in the untreated group and 55 per cent in the treated group. In this study, early treatment of CLL with intermittent chlorambucil did not result in a survival advantage for patients with indolent stage I and II CLL.
Similar articles
- Management of CLL patients after chlorambucil therapy. Special value of a second RAI staging.
Michallet M, Sotto JJ, Moulin JJ, Arvieux J, Hollard D. Michallet M, et al. Eur J Cancer (1965). 1980 Apr;16(4):511-7. doi: 10.1016/0014-2964(80)90230-3. Eur J Cancer (1965). 1980. PMID: 7398721 No abstract available. - Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P. Dighiero G, et al. N Engl J Med. 1998 May 21;338(21):1506-14. doi: 10.1056/NEJM199805213382104. N Engl J Med. 1998. PMID: 9593789 Clinical Trial. - Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L, Gurion R, Ram R, Raanani P, Bairey O, Robak T, Gafter-Gvili A, Shpilberg O. Vidal L, et al. Leuk Lymphoma. 2016 Sep;57(9):2047-57. doi: 10.3109/10428194.2016.1154956. Epub 2016 Mar 16. Leuk Lymphoma. 2016. PMID: 26980554 Review.
Cited by
- Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis.
Sciaccotta R, Gangemi S, Penna G, Giordano L, Pioggia G, Allegra A. Sciaccotta R, et al. Antioxidants (Basel). 2024 Apr 17;13(4):475. doi: 10.3390/antiox13040475. Antioxidants (Basel). 2024. PMID: 38671922 Free PMC article. Review. - Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study.
Crane JC, Gordon MJ, Basen-Engquist K, Ferrajoli A, Markofski MM, Lee CY, Fares S, Simpson RJ, LaVoy EC. Crane JC, et al. Eur J Haematol. 2023 Jun;110(6):732-742. doi: 10.1111/ejh.13958. Epub 2023 Mar 31. Eur J Haematol. 2023. PMID: 36946440 Free PMC article. - Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia.
Sitlinger A, Deal MA, Garcia E, Connelly M, Thompson D, Stewart T, Macdonald G, Hanson ED, Neely M, Neely B, Artese A, Weinberg JB, Brander D, Bartlett DB. Sitlinger A, et al. Front Oncol. 2022 Aug 3;12:933619. doi: 10.3389/fonc.2022.933619. eCollection 2022. Front Oncol. 2022. PMID: 35992862 Free PMC article. - Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells.
van Bruggen JAC, van der Windt GJW, Hoogendoorn M, Dubois J, Kater AP, Peters FS. van Bruggen JAC, et al. Blood Adv. 2022 Jul 26;6(14):4185-4195. doi: 10.1182/bloodadvances.2022007034. Blood Adv. 2022. PMID: 35580333 Free PMC article. Clinical Trial. - Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.
Ladyzynski P, Molik M, Foltynski P. Ladyzynski P, et al. Sci Rep. 2022 Feb 2;12(1):1811. doi: 10.1038/s41598-022-05813-8. Sci Rep. 2022. PMID: 35110619 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical